CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akela Pharma Inc (USA) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akela Pharma Inc (USA)
11501 Domain Dr Ste 130
Phone: (512) 531-6676p:512 531-6676 AUSTIN, TX  78758-3484  United States Fax: (512) 339-3050f:512 339-3050

On February 7, 2013, Formulation Technologies, LLC d/b/a PharmaForm, the primary operating subsidiary of Akela Pharma, Inc., was notified by Alliance Diversified Holdings LLC that it was in default of the Facility Lease entered into on December 13, 2012 between the Company and Alliance. On February 7, 2013, Formulation Technologies, LLC was notified by Biotech Investment Group, LLC, that as a result of being in default of the Facility Lease, it was also in default of terms of the Loan and Security Agreement dated December 13, 2012. On March 9, 2013, the asset foreclosure on Formulation Technologies, LLC d/b/a PharmaForm was completed. As a result, Akela Pharma, Inc. and its subsidiaries have ceased operations. All employees, officers and directors of Akela Pharma, Inc. have resigned or have been terminated.

Business Summary
Akela Pharma, Inc. (Akela) is a drug development company. The Company is a pharmaceutical formulation developer as well as clinical and commercial drug manufacturer for drug products through its PharmaForm subsidiary. PharmaForm engaged in the area of pharmaceutical dosage form development, controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid filled capsules. The Company has a pipeline also includes a growth hormone releasing hormone (GHRH), which is being developed for frailty and wasting in chronic renal disease. PharmaForm, is the Company’s wholly owned subsidiary which is engaged in Formulation and process development/optimization, Handling of potent compounds, Analytical testing, Clinical labeling and packaging and Patent litigation support. On August 9, 2011, the Company discontinued the Fentanyl TAIFUN program. PharmaForm, is the Company’s wholly owned subsidiary.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201212/31/2011YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Seth E.Lemler 44 7/17/2012 7/17/2012
Chief Scientific Officer James B.West 12/1/2011 12/1/2011
Independent Director Gordon H.Busenbark 6/25/2009 6/25/2009

Business Names
Business Name
Akela Pharma Inc.
AKLPF

General Information
Number of Employees: 65 (As of 12/31/2010)
Outstanding Shares: 32,390,338 (As of 6/30/2012)
Stock Exchange: OTC
Fax Number: (512) 339-3050


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023